Biological Roles and Clinical Applications of EpCAM in HCC

Overview

Journal Discov Oncol

Publisher Springer

Specialty Oncology

Date 2025 Mar 15

PMID 40087210

Authors

Peng Liu

Qun Zhang

Fengchao Liu

Affiliations

Soon will be listed here.

Abstract

Epithelial cell adhesion molecule (EpCAM) is an important biomarker in tumors. In hepatocellular carcinoma (HCC), EpCAM + cells exhibit high invasiveness, tumorigenic ability, therapeutic resistance, and self-renewal ability, often identified as liver cancer stem cells (CSCs). Detecting EpCAM + cells in tumor lesions and circulation is valuable for predicting patient prognosis and monitoring therapeutic outcomes, emphasizing its clinical significance. Given its broad expression in HCC, especially in CSCs and circulating tumor cells (CTCs), EpCAM-targeting agents have garnered substantial research interest. However, the role of EpCAM in HCC progression and its regulatory mechanisms remains poorly understood. Furthermore, clinical applications of EpCAM, such as liquid biopsy and targeted therapies, are still controversial. This review summarizes the biological properties of EpCAM + HCC cells, explores the regulatory mechanisms governing EpCAM expression, and discusses its clinical significance of using EpCAM as a prognostic marker and therapeutic target.

References

Bruix J, Sherman M . Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3):1020-2. PMC: 3084991. DOI: 10.1002/hep.24199. View

Llovet J, Kelley R, Villanueva A, Singal A, Pikarsky E, Roayaie S . Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. DOI: 10.1038/s41572-020-00240-3. View

Xu R, Wei W, Krawczyk M, Wang W, Luo H, Flagg K . Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat Mater. 2017; 16(11):1155-1161. DOI: 10.1038/nmat4997. View

Lee Y, Fujiwara N, Yang J, Hoshida Y . Risk stratification and early detection biomarkers for precision HCC screening. Hepatology. 2022; 78(1):319-362. PMC: 9995677. DOI: 10.1002/hep.32779. View

Craig A, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A . Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019; 17(3):139-152. DOI: 10.1038/s41575-019-0229-4. View

Chan L, Tsui Y, Ho D, Ng I . Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol. 2021; 82:134-149. DOI: 10.1016/j.semcancer.2021.02.015. View

Prasetyanti P, Medema J . Intra-tumor heterogeneity from a cancer stem cell perspective. Mol Cancer. 2017; 16(1):41. PMC: 5314464. DOI: 10.1186/s12943-017-0600-4. View

Gu Y, Zheng X, Ji J . Liver cancer stem cells as a hierarchical society: yes or no?. Acta Biochim Biophys Sin (Shanghai). 2020; 52(7):723-735. DOI: 10.1093/abbs/gmaa050. View

Nio K, Yamashita T, Kaneko S . The evolving concept of liver cancer stem cells. Mol Cancer. 2017; 16(1):4. PMC: 5282887. DOI: 10.1186/s12943-016-0572-9. View

10.

Herlyn M, Steplewski Z, Herlyn D, KOPROWSKI H . Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A. 1979; 76(3):1438-42. PMC: 383267. DOI: 10.1073/pnas.76.3.1438. View

11.

Gires O, Pan M, Schinke H, Canis M, Baeuerle P . Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years?. Cancer Metastasis Rev. 2020; 39(3):969-987. PMC: 7497325. DOI: 10.1007/s10555-020-09898-3. View

12.

Gaber A, Lenarcic B, Pavsic M . Current View on EpCAM Structural Biology. Cells. 2020; 9(6). PMC: 7349879. DOI: 10.3390/cells9061361. View

13.

Liu Y, Wang Y, Sun S, Chen Z, Xiang S, Ding Z . Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside. Exp Hematol Oncol. 2022; 11(1):97. PMC: 9650829. DOI: 10.1186/s40164-022-00352-4. View

14.

Bae J, Noh S, Jang K, Park H, Chung M, Park C . Expression and role of epithelial cell adhesion molecule in dysplastic nodule and hepatocellular carcinoma. Int J Oncol. 2012; 41(6):2150-8. DOI: 10.3892/ijo.2012.1631. View

15.

Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang H . EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology. 2009; 136(3):1012-24. PMC: 2828822. DOI: 10.1053/j.gastro.2008.12.004. View

16.

Kimura O, Takahashi T, Ishii N, Inoue Y, Ueno Y, Kogure T . Characterization of the epithelial cell adhesion molecule (EpCAM)+ cell population in hepatocellular carcinoma cell lines. Cancer Sci. 2010; 101(10):2145-55. PMC: 11159121. DOI: 10.1111/j.1349-7006.2010.01661.x. View

17.

Matsumoto T, Takai A, Eso Y, Kinoshita K, Manabe T, Seno H . Proliferating EpCAM-Positive Ductal Cells in the Inflamed Liver Give Rise to Hepatocellular Carcinoma. Cancer Res. 2017; 77(22):6131-6143. DOI: 10.1158/0008-5472.CAN-17-1800. View

18.

Khosla R, Rastogi A, Ramakrishna G, Pamecha V, Mukhopadhyay A, Vasudevan M . EpCAM+ Liver Cancer Stem-Like Cells Exhibiting Autocrine Wnt Signaling Potentially Originate in Cirrhotic Patients. Stem Cells Transl Med. 2017; 6(3):807-818. PMC: 5442787. DOI: 10.1002/sctm.16-0248. View

19.

Wendum D, Layese R, Ganne-Carrie N, Bourcier V, Merabtene F, Cagnot C . Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort). Hepatology. 2018; 68(4):1534-1548. DOI: 10.1002/hep.29927. View

20.

Ogasawara S, Akiba J, Nakayama M, Nakashima O, Torimura T, Yano H . Epithelial cell adhesion molecule-positive human hepatic neoplastic cells: development of combined hepatocellular-cholangiocarcinoma in mice. J Gastroenterol Hepatol. 2014; 30(2):413-20. DOI: 10.1111/jgh.12692. View